Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6
Authors
Keywords
-
Journal
Communications Biology
Volume 3, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-15
DOI
10.1038/s42003-020-01308-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
- (2018) Hirotake Tsukamoto et al. CANCER RESEARCH
- Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
- (2018) Kei Kunimasa et al. INVESTIGATIONAL NEW DRUGS
- Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
- (2018) Jason E. Hawkes et al. JOURNAL OF IMMUNOLOGY
- Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review
- (2018) Michitaro Hayakawa et al. RHEUMATOLOGY INTERNATIONAL
- A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
- (2018) Alice Horisberger et al. Journal for ImmunoTherapy of Cancer
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Therapeutic Antibodies against Intracellular Tumor Antigens
- (2017) Iva Trenevska et al. Frontiers in Immunology
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Targeting CD8+ T cells prevents psoriasis development
- (2016) Paola Di Meglio et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
- (2016) Omar Hasan Ali et al. OncoImmunology
- Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells
- (2015) Yasutomo Imai et al. JOURNAL OF IMMUNOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma
- (2015) Mikio Ohtsuka et al. JAMA Dermatology
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma
- (2015) James Larkin et al. JAMA Oncology
- Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes
- (2014) Naoko Okiyama et al. JOURNAL OF AUTOIMMUNITY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8+ T Cell Function
- (2014) Jan P. Böttcher et al. Cell Reports
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis
- (2013) Barry Flutter et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CD8+ T Cells Mediate RAS-Induced Psoriasis-Like Skin Inflammation through IFN-γ
- (2012) Andrew J. Gunderson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD4 T-Cell Help Programs a Change in CD8 T-Cell Function Enabling Effective Long-Term Control of Murine Gammaherpesvirus 68: Role of PD-1-PD-L1 Interactions
- (2010) P. Dias et al. JOURNAL OF VIROLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
- (2009) L. van der Fits et al. JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek
- (2008) G. J. Freeman PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search